Up-regulation of type II collagen gene by 17β-estradiol in articular chondrocytes involves Sp1/3, Sox-9, and estrogen receptor α

Journal of Molecular Medicine

Volumn 92, Issue 11, 2014, Pages 1179-1200

  Maneix, Laure ^a   Servent, Aurélie ^a   Porée, Benoît ^a   Ollitrault, David ^a   Branly, Thomas ^a   Bigot, Nicolas ^a   Boujrad, Noureddine ^b   Flouriot, Gilles ^b   Demoor, Magali ^a   Boumediene, Karim ^a   Moslemi, Safa ^a   Galéra, Philippe ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

17 estradiol; Cartilage; Chondrocytes; Estrogen receptor ; Osteoarthritis; Sox proteins; Sp1 Sp3; Type II collagen (COL2A1) gene

Indexed keywords

COLLAGEN TYPE 2; DNA BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; COL2A1 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; SOX9 PROTEIN, HUMAN; SP1 PROTEIN, HUMAN; SP3 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CARTILAGE CELL; CELL DEDIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVATION; IN VIVO STUDY; INTRON; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RABBIT; UPREGULATION; ANIMAL; ARTICULAR CARTILAGE; CELL DIFFERENTIATION; CHONDROCYTE; CYTOLOGY; GENETICS; HUMAN; MALE; METABOLISM; TRANSCRIPTION INITIATION;

ANIMALS; BINDING SITES; CARTILAGE, ARTICULAR; CELL DIFFERENTIATION; CHONDROCYTES; COLLAGEN TYPE II; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; MALE; PHENOTYPE; PROMOTER REGIONS, GENETIC; RABBITS; RNA, SMALL INTERFERING; SOX9 TRANSCRIPTION FACTOR; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84919868374     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-014-1195-5     Document Type: Article

References (58)

1. Goldwasser M, Astley T, Van der Rest M, Glorieux FH (1982) Analysis of the type of collagen present in osteoarthritic human cartilage. Clin Orthop Relat Res 167:296–302
2. Von der Mark K, Kirsch T, Nerlich A, Kuss A, Weseloh G, Gluckert K, Stoss H (1992) Type X collagen synthesis in human osteoarthritic cartilage. Indication of chondrocyte hypertrophy. Arthritis Rheum 35:806–811
3. Ala-Kokko L, Kvist AP, Metsaranta M, Kivirikko KI, De Crombrugghe B, Prockop DJ, Vuorio E (1995) Conservation of the sizes of 53 introns and over 100 intronic sequences for the binding of common transcription factors in the human and mouse genes for type II procollagen (COL2A1). Biochem J 308(Pt 3):923–929
4. Ryan MC, Sieraski M, Sandell LJ (1990) The human type II procollagen gene: identification of an additional protein-coding domain and location of potential regulatory sequences in the promoter and first intron. Genomics 8:41–48
5. Ghayor C, Herrouin JF, Chadjichristos C, Ala-Kokko L, Takigawa M, Pujol JP, Galera P (2000) Regulation of human COL2A1 gene expression in chondrocytes. Identification of C-Krox-responsive elements and modulation by phenotype alteration. J Biol Chem 275:27421–27438
6. Ghayor C, Chadjichristos C, Herrouin JF, Ala-Kokko L, Suske G, Pujol JP, Galera P (2001) Sp3 represses the Sp1-mediated transactivation of the human COL2A1 gene in primary and de-differentiated chondrocytes. J Biol Chem 276:36881–36895
7. Lefebvre V, Li P, De Crombrugghe B (1998) A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J 17:5718–5733
8. Poree B, Kypriotou M, Chadjichristos C, Beauchef G, Renard E, Legendre F, Melin M, Gueret S, Hartmann DJ, Mallein-Gerin F et al (2008) Interleukin-6 (IL-6) and/or soluble IL-6 receptor down-regulation of human type II collagen gene expression in articular chondrocytes requires a decrease of Sp1.Sp3 ratio and of the binding activity of both factors to the COL2A1 promoter. J Biol Chem 283:4850–4865
9. Bay-Jensen AC, Tabassi NC, Sondergaard LV, Andersen TL, Dagnaes-Hansen F, Garnero P, Kassem M, Delaisse JM (2009) The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther 11:R9
10. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C (2003) Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 62:332–336
11. Sandmark H, Hogstedt C, Lewold S, Vingard E (1999) Osteoarthrosis of the knee in men and women in association with overweight, smoking, and hormone therapy. Ann Rheum Dis 58:151–155
12. Von Muhlen D, Morton D, Von Muhlen CA, Barrett-Connor E (2002) Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women. J Womens Health Gend Based Med 11:511–518
13. Le Bail J, Liagre B, Vergne P, Bertin P, Beneytout J, Habrioux G (2001) Aromatase in synovial cells from postmenopausal women. Steroids 66:749–757
14. Ham KD, Loeser RF, Lindgren BR, Carlson CS (2002) Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum 46:1956–1964
15. Fernihough JK, Richmond RS, Carlson CS, Cherpes T, Holly JM, Loeser RF (1999) Estrogen replacement therapy modulation of the insulin-like growth factor system in monkey knee joints. Arthritis Rheum 42:2103–2111
16. Yaeger PC, Masi TL, De Ortiz JL, Binette F, Tubo R, McPherson JM (1997) Synergistic action of transforming growth factor-beta and insulin-like growth factor-I induces expression of type II collagen and aggrecan genes in adult human articular chondrocytes. Exp Cell Res 237:318–325
17. Renard E, Poree B, Chadjichristos C, Kypriotou M, Maneix L, Bigot N, Legendre F, Ollitrault D, De Crombrugghe B, Mallein-Gerin F et al (2012) Sox9/Sox6 and Sp1 are involved in the insulin-like growth factor-I-mediated upregulation of human type II collagen gene expression in articular chondrocytes. J Mol Med (Berlin, Germany) 90:649–666
18. Saggese G, Federico G, Cinquanta L (1993) In vitro effects of growth hormone and other hormones on chondrocytes and osteoblast-like cells. Acta Paediatr (Oslo, Norway) 82(Suppl 391):54–59
19. Dayani N, Corvol MT, Robel P, Eychenne B, Moncharmont B, Tsagris L, Rappaport R (1988) Estrogen receptors in cultured rabbit articular chondrocytes: influence of age. J Steroid Biochem 31:351–356
20. Ushiyama T, Ueyama H, Inoue K, Ohkubo I, Hukuda S (1999) Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. Osteoarthritis Cartilage 7:560–566
21. Sniekers YH, Van Osch GJ, Ederveen AG, Inzunza J, Gustafsson JA, Van Leeuwen JP, Weinans H (2009) Development of osteoarthritic features in estrogen receptor knockout mice. Osteoarthritis Cartilage 17:1356–1361
22. O'Lone R, Frith MC, Karlsson EK, Hansen U (2004) Genomic targets of nuclear estrogen receptors. Mol Endocrinol (Baltimore, Md) 18:1859–1875
23. Galien R, Garcia T (1997) Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 25:2424–2429
24. Li D, Mitchell D, Luo J, Yi Z, Cho SG, Guo J, Li X, Ning G, Wu X, Liu M (2007) Estrogen regulates KiSS1 gene expression through estrogen receptor alpha and SP protein complexes. Endocrinology 148:4821–4828
25. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F (2000) Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J 19:4688–4700
26. Denger S, Reid G, Kos M, Flouriot G, Parsch D, Brand H, Korach KS, Sonntag-Buck V, Gannon F (2001) ERalpha gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins. Mol Endocrinol (Baltimore, Md) 15:2064–2077
27. Maneix L, Beauchef G, Servent A, Wegrowski Y, Maquart FX, Boujrad N, Flouriot G, Pujol JP, Boumediene K, Galera P et al (2008) 17Beta-oestradiol up-regulates the expression of a functional UDP-glucose dehydrogenase in articular chondrocytes: comparison with effects of cytokines and growth factors. Rheumatology (Oxford, England) 47:281–288
28. Chadjichristos C, Ghayor C, Kypriotou M, Martin G, Renard E, Ala-Kokko L, Suske G, De Crombrugghe B, Pujol JP, Galera P (2003) Sp1 and Sp3 transcription factors mediate interleukin-1 beta down-regulation of human type II collagen gene expression in articular chondrocytes. J Biol Chem 278:39762–39772
29. Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499
30. Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H, Papa MZ (2006) Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J Endocrinol 191:605–612
31. Marino M, Galluzzo P, Ascenzi P (2006) Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 7:497–508
32. Porter W, Saville B, Hoivik D, Safe S (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol (Baltimore, Md) 11:1569–1580
33. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB (1998) Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273:10696–10701
34. Lu S, Jenster G, Epner DE (2000) Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol (Baltimore, Md) 14:753–760
35. Kim K, Thu N, Saville B, Safe S (2003) Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol Endocrinol (Baltimore, Md) 17:804–817
36. Chadjichristos C, Ghayor C, Herrouin JF, Ala-Kokko L, Suske G, Pujol JP, Galera P (2002) Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio. J Biol Chem 277:43903–43917
37. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G, Safe S (2000) Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem 275:22769–22779
38. Schultz JR, Petz LN, Nardulli AM (2003) Estrogen receptor alpha and Sp1 regulate progesterone receptor gene expression. Mol Cell Endocrinol 201:165–175
39. Higgins KJ, Liu S, Abdelrahim M, Vanderlaag K, Liu X, Porter W, Metz R, Safe S (2008) Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins. Mol Endocrinol (Baltimore, Md) 22:388–402
40. Kypriotou M, Fossard-Demoor M, Chadjichristos C, Ghayor C, De Crombrugghe B, Pujol JP, Galera P (2003) SOX9 exerts a bifunctional effect on type II collagen gene (COL2A1) expression in chondrocytes depending on the differentiation state. DNA Cell Biol 22:119–129
41. Bi W, Deng JM, Zhang Z, Behringer RR, De Crombrugghe B (1999) Sox9 is required for cartilage formation. Nat Genet 22:85–89
42. Lafont JE, Talma S, Murphy CL (2007) Hypoxia-inducible factor 2alpha is essential for hypoxic induction of the human articular chondrocyte phenotype. Arthritis Rheum 56:3297–3306
43. Hattori T, Muller C, Gebhard S, Bauer E, Pausch F, Schlund B, Bosl MR, Hess A, Surmann-Schmitt C, Von der Mark H et al (2010) SOX9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification. Development (Cambridge, England) 137:901–911
44. Savagner P, Krebsbach PH, Hatano O, Miyashita T, Liebman J, Yamada Y (1995) Collagen II promoter and enhancer interact synergistically through Sp1 and distinct nuclear factors. DNA Cell Biol 14:501–510
45. Leung KK, Ng LJ, Ho KK, Tam PP, Cheah KS (1998) Different cis-regulatory DNA elements mediate developmental stage- and tissue-specific expression of the human COL2A1 gene in transgenic mice. J Cell Biol 141:1291–1300
46. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E et al (1998) Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol (Baltimore, Md) 12:1605–1618
47. Kobayashi Y, Kitamoto T, Masuhiro Y, Watanabe M, Kase T, Metzger D, Yanagisawa J, Kato S (2000) p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. J Biol Chem 275:15645–15651
48. Kim MY, Hsiao SJ, Kraus WL (2001) A role for coactivators and histone acetylation in estrogen receptor alpha-mediated transcription initiation. EMBO J 20:6084–6094
49. Tsuda M, Takahashi S, Takahashi Y, Asahara H (2003) Transcriptional co-activators CREB-binding protein and p300 regulate chondrocyte-specific gene expression via association with Sox9. J Biol Chem 278:27224–27229
50. Furumatsu T, Tsuda M, Yoshida K, Taniguchi N, Ito T, Hashimoto M, Ito T, Asahara H (2005) Sox9 and p300 cooperatively regulate chromatin-mediated transcription. J Biol Chem 280:35203–35208
51. Achari Y, Lu T, Katzenellenbogen BS, Hart DA (2009) Distinct roles for AF-1 and -2 of ER-alpha in regulation of MMP-13 promoter activity. Biochim Biophys Acta 1792:211–220
52. Billon-Gales A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G, Gourdy P, Lenfant F, Laurell H, Krust A et al (2009) The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc Natl Acad Sci U S A 106:2053–2058
53. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol (Baltimore, Md) 8:21–30
54. Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811–2818
55. Jiang HP, Teng RY, Wang Q, Zhang X, Wang HH, Cao J, Teng LS (2008) Estrogen receptor alpha variant ERalpha46 mediates growth inhibition and apoptosis of human HT-29 colon adenocarcinoma cells in the presence of 17beta-oestradiol. Chin Med J 121:1025–1031
56. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson JA, Nilsson S et al (1999) The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol (Baltimore, Md) 13:1672–1685
57. Takeuchi S, Mukai N, Tateishi T, Miyakawa S (2007) Production of sex steroid hormones from DHEA in articular chondrocyte of rats. Am J Physiol Endocrinol Metab 293:E410–E415
58. Richette P, Laborde K, Boutron C, Bardin T, Corvol MT, Savouret JF (2007) Correlation between serum and synovial fluid estrogen concentrations: comment on the article by Sowers et al. Arthritis Rheum 56:698, author reply 698–699